Truist raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $520 from $460 and keeps a Buy rating on the shares. The firm is positive on the launch of Journavx, which is seeing “broad ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback